Plasma osteopontin: Associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma

Cancer

Volumn 95, Issue 3, 2002, Pages 506-512

  Hotte, Sebastien J ^a   Winquist, Eric W ^a,b   Stitt, Larry ^b   Wilson, Sylvia M ^a   Chambers, Ann F ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Blood assay; Bone metastases; Osteopontin; Prognostic factor; Prostate carcinoma

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN; LACTATE DEHYDROGENASE; OSTEOPONTIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE METASTASIS; CANCER SURVIVAL; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BONE NEOPLASMS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; OSTEOPONTIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS;

EID: 0036682303     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10709     Document Type: Article

References (37)

1. Cancer statistics, 2000
2. Management of hormone refractory prostate cancer: Current standards and future prospects
3. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer
4. Prognostic factors in stage D2 prostate cancer; important implications for future trials: Results of a cooperative Intergroup Study (INT.0036)
5. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer
6. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints
7. Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin
8. Change in serum prostate-specific antigen as a marker of response to cytotoxic chemotherapy for hormone-refractory prostate cancer
9. Relationship between changes in serum prostatic specific antigen and palliative response following treatment of symptomatic hormone-refractory prostate cancer
10. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A Phase II trial
11. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer
12. Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation
13. The nature and significance of osteopontin
14. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation
15. Inhibition of calcium oxalate crystal growth in vitro by uropontin: Another member of the aspartic acid-rich protein superfamily
16. Osteopontin expression detected in adult cochleae and inner ear fluids
17. Quantification of osteopontin in human plasma with an ELISA: Basal levels in pre- and postmenopausal women
18. Osteopontin
19. Osteopontin: A versatile regulator of inflammation and biomineralization
20. Evidence that a non-RGD domain in rat osteopontin is involved in cell attachment
21. Rat osteoblasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a β3 integrin
22. A biochemical characterization of the binding of osteopontin to integrin αvβ3, αvβ1, and αvβ5
23. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met)
24. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells
25. Receptor-ligand interaction between CD44 and osteopontin (Eta-1)
26. CD44 variants but not CD44s cooperate with β1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis
27. Molecular and cellular basis of genetic resistance to bacterial infection: The role of the early T-lymphocyte activation-1/osteopontin gene
28. Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue
29. NF-κB mediates αvβ3 integrin-induced endothelial cell survival
30. Osteopontin expression and distribution in human carcinomas
31. Osteopontin expression in a group of lymph node negative breast cancer patients
32. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival
33. Osteopontin stimulates a subpopulation of quiescent human prostate epithelial cells with high proliferative potential in vitro
34. Osteopontin: Possible role in prostate cancer progression
35. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues
36. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment